0001178913-23-001115.txt : 20230323 0001178913-23-001115.hdr.sgml : 20230323 20230323073842 ACCESSION NUMBER: 0001178913-23-001115 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230316 FILED AS OF DATE: 20230323 DATE AS OF CHANGE: 20230323 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Moses Alan Charles CENTRAL INDEX KEY: 0001819501 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38807 FILM NUMBER: 23754486 MAIL ADDRESS: STREET 1: C/O 7 PINHAS SAPIR ST., FLOOR 2 CITY: NESS ZIONA STATE: L3 ZIP: 7414002 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Chemomab Therapeutics Ltd. CENTRAL INDEX KEY: 0001534248 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813676773 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: KIRYAT ATIDIM, BUILDING 7 CITY: TEL AVIV STATE: L3 ZIP: 6158002 BUSINESS PHONE: 972-77-331-0156 MAIL ADDRESS: STREET 1: KIRYAT ATIDIM, BUILDING 7 CITY: TEL AVIV STATE: L3 ZIP: 6158002 FORMER COMPANY: FORMER CONFORMED NAME: Anchiano Therapeutics Ltd. DATE OF NAME CHANGE: 20180906 FORMER COMPANY: FORMER CONFORMED NAME: BioCancell Ltd. DATE OF NAME CHANGE: 20111104 4 1 zk2329430.xml X0407 4 2023-03-16 0 0001534248 Chemomab Therapeutics Ltd. CMMB 0001819501 Moses Alan Charles C/O CHEMOMAB THERAPEUTICS LTD. KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 ISRAEL 1 0 0 0 0 Option to Purchase American Depositary Shares 1.62 2023-03-16 4 A 0 6857 0 A 2033-03-21 American Depositary Shares 6857 6857 D Option to Purchase American Depositary Shares 3.53 2022-03-07 4 A 0 6820 0 A 2032-03-07 American Depositary Shares 6820 6820 D Option to Purchase American Depositary Shares 27.26 2021-04-19 4 A 0 11884 0 A 2031-04-19 American Depositary Shares 11884 11884 D These options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service. These options were granted as per the annual grant of options to directors. Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. These options vested and became exercisable in their entirety on March 16, 2023. These options were granted as per the annual grant of options to directors. These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service. /s/ Matthew Rudolph, Esq., Attorney-in-Fact for Alan Charles Moses 2023-03-23